Find Academic Supervisors

Richard J. SmeyneView profile

Professor

• Parkinson's Disease
• Neuroscience
• Cell Biology
• +4 more

Richard J. Smeyne serves as Professor and Chair of the Department of Neuroscience at Thomas Jefferson University, concurrently directing the Jefferson Comprehensive Parkinson’s Center within the Vickie and Jack Farber Institute for Neuroscience. His work centers on the cell biology of Parkinson's disease and neurodegenerative mechanisms. Dr. Smeyne's research investigates environmental and genetic interactions in Parkinson's pathogenesis, focusing on alpha-synuclein aggregation, neuroinflammation, and dopaminergic neuron death. His laboratory employs genetic mouse models, rotenone exposure systems, and neuroanatomical analyses to explore pathways like GUCY2C signaling and microglial regulation of autophagy. Key interests include SARS-CoV-2 neuropathology links, protein misfolding dynamics, and behavioral impacts of social isolation on neural systems. His publication trends reveal strong emphasis on molecular Parkinson's disease mechanisms, integrating toxicology, immunology, and cell biology. Recent work highlights alpha-synuclein templating effects, neuroprotective signaling cascades, and microglial roles in protein clearance, demonstrating consistent translational focus on therapeutic targets for neurodegeneration. While student mentorship details are unreported, his dual leadership roles as department chair and center director imply oversight of graduate researchers and substantial grant-funded projects. Dr. Smeyne maintains an active laboratory investigating Parkinson's disease pathogenesis through interdisciplinary approaches. He leads the Jefferson Comprehensive Parkinson’s Center research team, which examines environmental-genetic interplay in neurodegeneration. Current projects address inflammation triggers, dopamine neuron vulnerability, and autophagy dysregulation, utilizing advanced models to identify disease-modifying interventions.

• Cardiac Physiology
• Cardiovascular Metabolism
• Heart Failure
• +3 more

Craig Lygate is an Associate Professor of Cardiovascular Physiology at the University of Oxford's Division of Cardiovascular Medicine, leading the 'Cardiac Energetics and Integrative Physiology' research group funded by the British Heart Foundation. His work focuses on understanding cardiac energy metabolism's role in health and disease, particularly exploring therapies for ischaemia and heart failure. He heads the Murine Cardiac Phenotyping Laboratory, using clinical techniques like echocardiography and MRI to assess genetically modified models. Education includes a BSc (Hons), MRes in Biological Sciences (University of Manchester), and a PhD in Cardiovascular Physiology (University of Glasgow). His research combines biochemical assays, cell culture, and collaborative approaches such as genomics and metabolomics, with a current emphasis on the creatine transporter and homoarginine's therapeutic potential. Recent articles highlight advancements in nitric oxide delivery systems for cardiovascular applications and the creatine kinase system's role in cardiac energy provision. Collaborations with Chemistry departments target novel treatments for ischaemia-reperfusion injury. No scientific awards are explicitly listed, but his work has been published in high-impact journals like Circulation and Clinical Science . He advises postgraduate researchers (e.g., Hannah Lake) and oversees grants focused on cardiac energetics. His lab integrates translational research, bridging molecular biology with clinical applications, aiming to translate findings into therapeutic strategies for cardiovascular diseases.

• Pharmacology
• Chemotherapy
• Cytofluorimetry
• +3 more

Sabrina Pacor is an Associate Professor in Applied Biology (BIO/13) at the University of Trieste , where she teaches Pharmacology in the Pharmacy LM and STB BSc programs. With over 30 years of research experience in experimental oncology and host defense peptides, she has made significant contributions to studying antimicrobial peptides (AMPs) and their interactions with bacterial membranes. Her research focuses on: Direct antimicrobial activity of AMPs against Gram-positive and Gram-negative bacteria Indirect immunomodulatory effects of host defense peptides Development of drug delivery systems using nanomaterials (carbon nanotubes, gold nanoparticles) Mechanistic studies of ruthenium-based antimetastatic drugs She leads extensive cytofluorimetry research using flow cytometry platforms, particularly for evaluating: Cytotoxicity (necrosis/apoptosis, proliferation index) Modulation of host biological responses (chemotaxis, phagocytosis, ROS production) Peptide-bacterial membrane interactions through fluorescent labeling Her recent work demonstrates trends in: Proline-rich antimicrobial peptides against ESKAPE pathogens Hybrid antibiotic design (peptide-aminoglycoside conjugates) Structure-activity relationships in membranolytic peptides Evolutionary insights into defensin and cathelicidin families Prof. Pacor has co-authored over 100 peer-reviewed publications and actively mentors students, having supervised: 70 experimental/thesis reviews for Pharmacy/CTF Master's students 20 Bachelor's degree theses

• hearing loss
• vestibular dysfunction
• brain disorders
• +7 more

Dr. Saima Riazuddin is a Professor at the University of Maryland School of Medicine, with joint appointments in Otorhinolaryngology-Head & Neck Surgery and Biochemistry & Molecular Biology. Her research focuses on the molecular genetics of inherited disorders, particularly hearing loss, vestibular dysfunction, intellectual disability, and Usher syndrome, utilizing human genetics, mouse models, and zebrafish models to identify disease-causing genes and elucidate their functional mechanisms. PhD in Molecular Genetics (University of Punjab, Pakistan) MPH in Leadership Management & Policy (University of Cincinnati) MBA in Business Administration (University of Cincinnati) Her lab investigates the genetic factors determining hearing sensitivity, pathogenic mutations affecting ear/eye structure, and molecular mechanisms of auditory/vision functions. Publications in Nature Genetics , Cell , and Molecular Psychiatry highlight discoveries in genes like TRIOBP , CIB2 , and ELMOD3 linked to deafness syndromes. Scientific accolades include the Medal of Honor from Pakistan's President. Research spans linkage analysis, functional gene characterization, and therapeutic design for genetic hearing/visual impairments.

Hamed Jafar-NejadView profile

Professor

• Glycosylation
• Notch Signaling Pathway
• Developmental Biology
• +6 more

Hamed Jafar-Nejad is a Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine, affiliated with the Graduate School of Biomedical Sciences and the Program in Developmental Biology . He received his MD from Tehran University of Medical Sciences and completed postdoctoral training at the University of Ottawa and Baylor College of Medicine. Research Interests : Glycosylation and deglycosylation in Notch signaling, Alagille syndrome (biliary development), NGLY1 deficiency, and their roles in human disease pathophysiology. Key Projects : Development of mouse models for Alagille syndrome, identification of dosage-sensitive modifiers like Poglut1, and investigation of NGLY1's role in BMP and AMPK signaling using Drosophila and mouse models. Recent Publications focus on therapeutic strategies for Alagille syndrome via gene silencing, POGLUT1's role in muscular dystrophy, and deglycosylation's impact on metabolic and immune dysregulation. His work bridges Drosophila genetics and mammalian systems to uncover mechanisms for developmental disorders. Scientific Awards : Harrington Scholar-Innovator Award (2025), Alagille Syndrome Accelerator Awards (2019, 2015), Glycobiology Significant Achievement Award (2017), and others. Labs & Collaborations : Leads the Hamed Jafar-Nejad Lab, collaborating with Haltiwanger, Paradas, and Darabi groups. His team includes graduate students, postdoctoral fellows, and alumni now in academia and industry.

Anxo Vidal FigueroaView profile

Associate Professor

• Cell cycle regulation
• Tumor biology
• Stem cell biology
• +6 more

Anxo Vidal Figueroa is an Associate Professor of Physiology at the University of Santiago de Compostela, where he has been a permanent faculty member since 2008. He is affiliated with the Faculty of Medicine and Dentistry, Department of Physiology, and is part of the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS). Vidal leads the "MeMoEn" (Molecular Mechanisms of Disease) research group and previously contributed to the "FIFAEC" (Physiology and Pharmacology of Chronic Diseases) group. His academic journey began with a PhD in Cell Biology from the University of Santiago de Compostela in 1997, where he completed his thesis "Functional analysis of prothymosin alpha in cell cultures" under the supervision of Dr. Fernando Domínguez Puente and Dr. M. Clara Alvarez Villamarin. From 1998 to 2003, he pursued postdoctoral research at Memorial Sloan-Kettering Cancer Center in New York, working in the Laboratory of Cell Cycle Regulation under Dr. Andrew Koff. Vidal's research program focuses on understanding the molecular mechanisms of cancer development and progression, with particular emphasis on cell cycle regulation, tumor suppressor biology, and stem cell dynamics. His laboratory employs genetically modified mouse models to investigate how cell cycle regulators control cancer initiation, tissue homeostasis, and aging processes. In recent years, his work has expanded into nanomedicine and novel therapeutic strategies for advanced cancers, particularly through nanocarrier systems and immunotherapy approaches. Analysis of his recent publications reveals a strong trend toward translational cancer research, with increasing focus on nanomedicine applications (2022-2025). His work spans molecular mechanisms of tumor suppressors, cancer stem cell biology, and the development of innovative therapeutic tools including nanoengineered drug delivery systems, silver clusters as antitumoral agents, and immunotherapeutic approaches for pancreatic and ovarian cancers. 2006 Novartis Award in Endocrine Tumor Pathology Ranked #2 nationwide in Physiology for the Spanish "Ramon y Cajal" Program (2002) As a principal investigator, Vidal has secured competitive national and international research grants, including a Retos Colaboración grant with SunRock Biopharma and current grants for immunotherapy against ovarian cancer. He has supervised 16 PhD theses and mentored numerous researchers throughout his career. His laboratory, the Cell Cycle and Oncology group at CIMUS, focuses on five main research areas: mechanisms of p27Kip1 regulation, cooperative functions of cell cycle regulators, cell cycle-independent roles of CDK inhibitors in stem cell biology, molecular relationships between reprogramming and cancer, and development of new therapeutic tools in advanced cancer.

• Ion Transport Physiology
• Molecular Cell Biology
• Biophysics
• +3 more

Thomas J. Jentsch is a leading Professor at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, with secondary affiliation to the Max Delbrück Center (MDC) . He holds dual doctorates in Medicine and Physics from Freie Universität Berlin and has pioneered research in ion transport physiology since co-founding the Center for Molecular Neurobiology Hamburg in 1988. Head of Jentsch Group at FMP since 2006 World leader in chloride channel research His research bridges molecular physiology and human genetics , focusing on: CLC family chloride channels/transporters VRAC/LRRC8 volume-regulated channels ASOR/TMEM206 acid-activated channels Pathologies: neurodegeneration, deafness, osteopetrosis, hypertension Recent work includes breakthroughs in VRAC channel structure (2023) and CLCN7 channelopathies (2024). His lab employs genetically modified mouse models and human mutation analysis to uncover disease mechanisms.

Ola HermansonView profile

Professor

• Neurodevelopment
• Neuro-oncology
• Epigenetics
• +5 more

Ola Hermanson is a Professor of Neuroscience at the Department of Neuroscience, Karolinska Institutet. His research focuses on understanding transcriptional and epigenetic mechanisms governing brain development, function, and disease, including neurodevelopmental disorders and brain tumors like glioblastoma. He employs cutting-edge technologies such as 3D bioprinting, bioelectronics, and molecular biology to study neural stem cells and cancer stem cells. Education and Positions: Professor of Neuroscience, Karolinska Institutet (2021–present) Senior Scientist, Karolinska Institutet (2009–2021) Assistant Professor, Karolinska Institutet (2003–2009) Postdoctoral Training, UC San Diego (1997–2002) PhD in System Neurobiology, Linköping University (1991–1997) Medical School, Lund University (1987–1990) Research Interests: Neural stem cell differentiation, epigenetic regulation, glioblastoma and medulloblastoma biology, biomedical engineering, and biomaterials. His lab develops technologies like 3D printing and bioelectronics to advance precision medicine. Publications: Over 70 peer-reviewed articles in prestigious journals like Nature , Cell , and Molecular Psychiatry . Recent work includes lithium's role in reversing radiation damage in neural progenitors and bioprinting for tumor modeling. Awards: Includes the ENI Young Investigator Award (2005), Strategic Professorship (2021), and recognition from the Canadian Government for Sweden-Canada collaboration. Teaching and Outreach: Course coordinator for neuroscience education programs (FoLäk1/2, anatomy courses). Engaged in pedagogical innovation, including TBL-based learning and neurotech education through NeurotechEU. Labs/Teams: Leads the Molecular Neurodevelopment and Neuro-Oncology group at KI. Founded the imaging core facility CLICK and co-founded Celluminova (stem cell markers SME).

Christopher D. LinkView profile

Associate Professor

• Molecular Genetics
• Neurodegenerative Diseases
• Transgenic Models
• +3 more

Christopher D. Link is an Associate Professor in the Department of Integrative Physiology at the University of Colorado Boulder , affiliated with the Institute for Behavioral Genetics . His research focuses on understanding the cellular and molecular mechanisms of age-associated neurodegenerative diseases like Alzheimer's disease (AD) and Amyotrophic Lateral Sclerosis (ALS). University: University of Colorado Boulder Affiliation: Institute for Behavioral Genetics Department: Integrative Physiology Email: linkc@colorado.edu Dr. Link's lab develops Caenorhabditis elegans models expressing human disease proteins (e.g., beta amyloid in AD, TDP-43 in ALS) to identify genetic and molecular pathways driving pathology. These models enable high-throughput screening of modifiers and potential therapeutics, complemented by mammalian cell studies and bioinformatic analysis of deep sequencing data. Recent publications highlight his work on PKR signaling in sleep regulation (2023), TDP-43 knockdown mechanisms (2023), hydrogen sulfide supplementation (2022), and bisphenol A effects on aging (2022). His lab also investigates protein aggregation, neuroinflammation, and genetic modifiers of neurodegeneration. The Molecular Biology of Neurodegeneration Lab has contributed to understanding amyloid-β toxicity, TDP-43 functions in chromatin regulation (2018), and stress granule dynamics (2018). Collaborations span biofluid proteomics, induced pluripotent stem cell modeling, and transcriptomic analysis of ALS/FTLD pathologies.

Laurie A. BoyerView profile

Professor

• Developmental Biology
• Cardiovascular Biology
• Chromatin Remodeling
• +4 more

Laurie A. Boyer is a Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology (MIT), affiliated with the Koch Biology Building. She serves as Co-Undergraduate Officer and leads research on gene regulatory mechanisms in heart development and regeneration using embryonic stem cells and mouse models. Her work integrates genomic, genetic, biochemical, and cell biological approaches to understand chromatin dynamics and lineage commitment, with applications in cardiac tissue engineering and regeneration. Education: PhD, 2001, University of Massachusetts Medical School BS, 1990, Biomedical Science, Framingham State University Research Interests: Dr. Boyer’s research focuses on the interplay between chromatin remodeling, epigenetic regulation, and transcriptional networks that drive heart development. She investigates how ATP-dependent chromatin remodelers influence lineage specification and explores methods to stimulate cardiac regeneration. Her lab combines advanced genomic techniques with tissue engineering to model 3D cardiac architecture, aiming to uncover regulatory circuits underlying normal and diseased heart development. Publications: Her recent work includes breakthroughs in high-throughput expansion microscopy for scalable super-resolution imaging, metabolic modulation of mesenchymal stem cells for cartilage repair, and the role of long noncoding RNAs like Braveheart in cardiovascular lineage commitment. These studies span molecular mechanisms of chromatin dynamics to translational applications in regenerative medicine. Awards & Honors: Pew Scholars Award in the Biomedical Sciences (2008) Smith Family Award for Excellence in Biomedical Science (2009) Scientific American World’s 50 Top Leaders in Research (2006) Irvin and Helen Sizer Career Development Award (2012) Grants & Collaborations: Dr. Boyer oversees grants from organizations like the NIH and American Heart Association. She collaborates with teams on interdisciplinary projects, including tissue engineering and stem cell therapies. Her lab also develops innovative microscopy techniques to advance cellular imaging scalability. Labs & Teams: Her laboratory at MIT’s Koch Institute integrates computational biology, bioengineering, and molecular biology. The lab focuses on translating fundamental discoveries into clinical applications for heart disease and regeneration.

• Metabolism
• Molecular Medicine
• Exercise Physiology
• +5 more

Curtis Hughey serves as Assistant Professor of Medicine within the Division of Molecular Medicine, conducting interdisciplinary research at the nexus of metabolism, molecular physiology, and metabolic disease pathogenesis. His work bridges basic science with clinical implications through innovative methodologies in metabolomics and metabolic flux analysis. His research program critically examines: Mitochondrial metabolism in liver, skeletal muscle, and placental tissues Exercise-induced metabolic adaptations and dysregulation in obesity NAFLD pathogenesis mechanisms involving lipotoxicity and inflammation Metabolomic biomarker discovery for metabolic diseases Regulation of gluconeogenesis and glucose homeostasis Analysis of Hughey's recent publications (2019-2023) reveals a dominant focus on tissue-specific metabolic crosstalk, particularly hepatic-muscle interactions during exercise and disease states. His work consistently employs advanced techniques including 2 H/ 13 C flux analysis, untargeted metabolomics, and genetically modified mouse models to dissect molecular mechanisms. Recurring themes include the dual roles of metabolic enzymes (e.g., PEPCK, pyruvate carboxylase), the impact of dietary interventions on liver metabolism, and the discovery of analytical artifacts in lipidomics that could confound biomarker research.

• Acute Lymphoblastic Leukemia
• Pediatric Brain Tumors
• Genetic Heterogeneity
• +5 more

Stephen E. Sallan, MD , is a Professor of Pediatrics at Harvard Medical School and a Physician at Dana-Farber Cancer Institute and Children's Hospital . His career spans over five decades in pediatric hematology/oncology , with a focus on acute lymphoblastic leukemia (ALL) and pediatric brain tumors . Education : MD, Wayne State University School of Medicine (1967) Residencies : Boston Floating Hospital (1968), Children's Hospital of Philadelphia (1969), Hospital for Sick Children, London (1970) Fellowship : Pediatric Oncology, Children's Hospital/DFCI (1972) Leadership Roles : Chief of Staff (1995), Chairman of Medical Staff Executive Committee (1995), Chief of Staff Emeritus (2012) Dr. Sallan's research integrates genetic heterogeneity , disease recurrence , and drug resistance in ALL, with efforts to develop targeted therapies like tumor vaccines and antiangiogenesis agents. His work addresses long-term treatment toxicities (cardiac, skeletal, neurocognitive), particularly in survivors of childhood cancers. His 15 most recent publications (2024–2018) demonstrate ongoing engagement with pharmacogenomics, thrombosis risk models, dietary interventions, and molecular markers in brain tumors. Key subfields include TRK-C in medulloblastoma , asparaginase complications , and DFCI ALL Consortium Protocols . Scientific Awards : Distinguished Alumni Award, Wayne State University School of Medicine (1997) James Carreras Prize for International Pediatrician of the Year (1987) As a leader in pediatric leukemia research , Dr. Sallan has shaped treatment protocols that minimize late effects while improving survival. He collaborates with multidisciplinary teams in neuro-oncology and pharmacogenomics, maintaining active roles in clinical trials and laboratory investigations.

Marianne FyhnView profile

Professor

• Neurobiology
• Neuroscience
• Physiology
• +7 more

Marianne Fyhn is a Professor at the University of Oslo's Section of Physiology and Cell Biology within the Faculty of Mathematics and Natural Sciences. She leads the Centre for Integrative Neuroplasticity (CINPLA), a strategic research initiative integrating experimental biology with computational physics/mathematics to study brain information processing and plasticity. PhD in Neuroscience (NTNU, 2000-2005) MSc in Physiology (University of Tromsø, 1997-1999) Bachelor in Arctic Biology (University Courses in Svalbard, 1995-1996) BSc in Biology (University of Bergen/Oslo, 1992-1995) Her research focuses on neural plasticity mechanisms in cortical structures, using large-scale neuronal recordings and transcranial two-photon microscopy to study synaptic and population code changes during sensory learning. Key findings include discovering grid cells in mice and demonstrating how experience modifies cortical circuits for long-term memory. Recent publications analyze perineuronal nets' role in memory stabilization, grid cell conformal mapping, and topological population coding in visual cortex. These works reveal intersections between neural circuit dynamics , computational modeling , and neurodegenerative processes . 2008: European Brain and Behaviour Society Award 2007: Eppendorf-Science Prize in Neurobiology 2006: Donald B. Lindsley Prize & I.K. Lykke Award Fyhn serves as course manager for advanced courses including MBV1020 - Physiology and MBV4340 - Advanced Neurobiology . Her lab develops educational tools like Neuronify for neural circuit simulation and open-source platforms for electrophysiological data analysis.

David R. DeyleView profile

Associate Professor

• Gene Therapy
• Cell Therapy
• Genomic Editing
• +12 more

David R. Deyle, M.D., is an Associate Professor of Medical Genetics at Mayo Clinic in Rochester, Minnesota. He holds primary and joint appointments as a Consultant in the Department of Medical Genetics, Department of Molecular Medicine, Department of Cardiovascular Medicine, Department of Orthopedic Surgery, and Department of Pediatric and Adolescent Medicine. His multidisciplinary role reflects his integrative research in gene and cell therapy for genetic disorders. Dr. Deyle earned his M.D. from the University of Minnesota Medical School, completed residency in Internal Medicine and Pediatrics at the University of Minnesota, and underwent fellowship training in Medical Genetics at the University of Washington, Seattle. He is board-certified in Clinical Genetics and Genomics by the American Board of Medical Genetics and Genomics. His research focuses on developing gene and cell therapies through genomic editing in human stem cells. Key areas include treating osteogenesis imperfecta using iPSCs and AAV vectors, in vivo modeling of skeletal diseases, and oncolytic measles virus (MV-NIS) therapy for neurofibromatosis 1 (NF1) tumors. His work leverages CRISPR, TALENs, and adeno-associated virus (AAV) technologies to precisely modify the genome in mesenchymal and induced pluripotent stem cells for regenerative medicine applications. Analysis of his recent publications reveals a strong trend in clinical genomics, stem cell engineering, and translational gene therapy. His work spans rare genetic disorders such as Ehlers-Danlos syndrome, achondroplasia, and mucopolysaccharidosis, with a consistent emphasis on improving diagnostic and therapeutic pipelines through genomic innovation. Discovery Science Award, Regenerative Medicine Minnesota (2020–2022) Gene Therapy of Arthritis and Related Disorders Young Investigator Award (2008) NIH Loan Repayment Program Grant (2006) Summa Cum Laude, University of Minnesota (1993) Dr. Deyle has served as Principal Investigator on multiple NIH-funded grants, including projects on in vivo gene targeting for inherited bone disease and engineering pluripotent stem cells for osteogenesis imperfecta. He has also been a mentor and committee member in the American Society of Gene & Cell Therapy and has reviewed grants for NIH study sections (NIAMS, NINDS, NCMRR). His laboratory is part of the Center for Individualized Medicine and the Center for Regenerative Biotherapeutics at Mayo Clinic, where his team develops preclinical models and novel viral vector systems for genetic correction.

Chongmin HuanView profile

Assistant Professor

• Immunology
• Autoimmunity
• Molecular Biology
• +3 more

Chongmin Huan, PhD, MD, serves as Assistant Professor in the Department of Cell Biology at SUNY Downstate Health Sciences University's College of Medicine, with additional appointments as Principal Investigator and Graduate Student Supervisor in the School of Graduate Studies' Molecular and Cellular Biology Program. His research focuses on autoimmune disease mechanisms, particularly systemic lupus erythematosus (lupus), utilizing genetically modified mouse models and human clinical samples to investigate B cell tolerance pathways. Dr. Huan's primary research centers on sphingomyelin synthase 2 (SMS2) as a critical regulator of B cell tolerance in germinal centers. His seminal work demonstrates that SMS2 prevents lupus pathogenesis by activating protein kinase C delta (PKCd)-mediated apoptosis in autoreactive B cells. Current investigations examine SMS2/PKCd pathway impairment in lupus patients and its role in existing therapeutic mechanisms, with pharmacologic SMS2 activation showing promise in preclinical models. Analysis of his publication record reveals a consistent research trajectory in sphingolipid metabolism across immunology, gastroenterology, and cardiology. His work spans lupus pathogenesis, inflammatory bowel disease, pancreatitis, and atherosclerosis, consistently identifying sphingomyelin synthases as pivotal regulators of immune tolerance and inflammatory responses through molecular and in vivo approaches. No scientific awards were explicitly mentioned in the provided information. Dr. Huan actively mentors graduate researchers including PhD candidate Sailee Chavan and MD/PhD candidate Shreya Desikan. His collaborative team includes Dr. Christopher Roman (Cell Biology) and Dr. Ellen Ginzler (Medicine: Rheumatology). He teaches Histology and Physiology courses for the College of Medicine, specializing in small intestine and pancreas structure and carbohydrate/water/electrolyte absorption mechanisms. His laboratory employs advanced techniques including germinal center B cell purification protocols to investigate how sphingolipid metabolism governs immune tolerance. The research program maintains strong translational focus with ongoing efforts to develop SMS2-targeted therapies for lupus and related autoimmune conditions.